NO. 4 THE FORUM, ST. HELIER, Y9
Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
CMS Rescinds Billing Privileges Revocation for Novocure Inc.
FDA Approves Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Reg. FD
Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Appoints Company President Frank Leonard as Chief Executive Officer
Reports Third Quarter 2025 Financial Results
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS